ETF Series Solutions Trust Range Cancer Therapeutics ETF
CNCR
CNCR was delisted on the 27th of May, 2025.
20 hedge funds and large institutions have $11M invested in ETF Series Solutions Trust Range Cancer Therapeutics ETF in 2022 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 4 reducing their positions, and 4 closing their positions.
25% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 4
5.74% more ownership
Funds ownership: 40.9% → 46.63% (+5.7%)
0% more funds holding
Funds holding: 20 → 20 (0)
0% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 4
1% less capital invested
Capital invested by funds: $11M → $11M (-$60.8K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BL
BCWM LLC
Overland Park,
Kansas
|
+$1.85M |
| 2 |
CA
CoreCap Advisors
Southfield,
Michigan
|
+$140K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$43.8K |
| 4 |
CG
Colony Group
Boston,
Massachusetts
|
+$41.7K |
| 5 |
PAG
Private Advisor Group
Morristown,
New Jersey
|
+$28.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$257K |
| 2 |
PFS
Prospera Financial Services
Dallas,
Texas
|
-$180K |
| 3 |
Osaic Holdings
Scottsdale,
Arizona
|
-$35.2K |
| 4 |
RFWA
RPg Family Wealth Advisory
Burlington,
Massachusetts
|
-$34.2K |
| 5 |
Koshinski Asset Management
Decatur,
Illinois
|
-$13.5K |
CNCR Hedge Fund Activity: Q2 2022 in Review
20 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) for Q2 2022, worth a combined $11M — down 0.55% from $11M a quarter earlier.
Fund positioning in CNCR was balanced in Q2 2022: 4 funds opened new positions, 4 closed out, 5 added to existing stakes and 4 trimmed.
The largest buyer was BCWM LLC, adding an estimated $1.85M. The largest seller was Citadel Advisors, exiting entirely with an estimated $257K sold.
- 20 institutional investors held ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) as of Q2 2022, unchanged from Q1 2022.
- Funds reported $11M of ETF Series Solutions Trust Range Cancer Therapeutics ETF stock for Q2 2022, down 0.55% quarter-over-quarter.
- 4 funds opened new ETF Series Solutions Trust Range Cancer Therapeutics ETF positions in Q2 2022 and 4 closed out, a net change of 0 holders.
- The largest ETF Series Solutions Trust Range Cancer Therapeutics ETF buyer in Q2 2022 was BCWM LLC, an estimated $1.85M added.
- The largest ETF Series Solutions Trust Range Cancer Therapeutics ETF seller in Q2 2022 was Citadel Advisors, an estimated $257K sold.
Based on aggregated 13F filings for Q2 2022.